Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

This study has been completed.
Information provided by:
Institute for Neurodegenerative Disorders Identifier:
First received: November 8, 2007
Last updated: July 23, 2008
Last verified: July 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2008
  Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)